Bone Biospecific Agents for MRI Contrast Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic methods for bone-related diseases, such as osteoporosis and osteosarcoma, lack specificity and efficacy in imaging and treating bone tissues due to non-targeted contrast agents used in MRI and CT imaging, which fail to accurately detect bone remodeling activities and pathological conditions.
Innovation Solution
Development of bone biospecific agents comprising a contrast material core surrounded by a polymeric shell functionalized with bone-targeting peptides, allowing for specific recognition and targeting of bone cells and mineralized bone extracellular matrix, enabling improved imaging and therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If non-targeted contrast agents are used in MRI and CT imaging, then imaging coverage is achieved, but imaging specificity and resolution for bone tissues deteriorates
Solution Approach 1:
The contrast agent is segmented into distinct functional components: a core contrast material (for imaging signal), a polymeric shell (for stability and targeting), and bone-specific peptides (for specificity). This segmentation allows each component to perform its specialized function, achieving high bone imaging resolution without excessive overall complexity.
Solution Approach 2:
The invention uses composite material structure combining inorganic contrast agents (iron oxide, gadolinium, gold, or iodine) with organic polymeric shells and peptide ligands. This composite approach integrates the imaging capabilities of inorganic materials with the biocompatibility and targeting specificity of organic materials, resolving the contradiction between imaging precision and structural complexity.
2Reliability
If current CT contrast agents are used, then imaging speed is maintained, but renal toxicity and vascular permeation increase
Solution Approach 1:
The invention changes the physicochemical parameters of contrast agents by enclosing them in polymeric shells with controlled size (nanoparticle or submicron scale) and surface properties. This modification reduces renal toxicity while maintaining imaging efficiency, as the shell protects the core contrast material and enables controlled renal clearance.
3Measurement precision
If non-specific contrast agents are used, then general imaging is achieved, but bone-specific detection capability deteriorates
Solution Approach 1:
The polymeric shell is functionally differentiated with specific bone-targeting peptides attached to its surface, creating local specificity while maintaining overall agent stability. This local quality approach allows the agent to specifically recognize bone cells and mineralized matrix without requiring complete restructuring of the entire agent system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bone biospecific agents enhance imaging resolution, enable early diagnosis, and provide therapeutic options for bone diseases by specifically interacting with bone cells and tissues, inhibiting osteoclast activity and facilitating bone repair processes.
Implementation Method 1
MRI is based on the ability of large magnetic fields to produce a net magnetic vector temporarily changing the alignment of the protons in the highly hydrated tissues
Implementation Method 2
CT is based on X-ray attenuation which is detected by a detector where the value of pixels is calculated and then transformed into an image
Implementation Method 3
functionalised with a bone-targeting peptide, wherein the peptide, in use, targets the biosspecific agent to bone
Data Source
AI summary
A bone biospecific agent comprises a contrast material core, which is visible using Magnetic Resonance Imaging (MRI) or Computed Tomography (CT). The contrast material core is surrounded by a polymeric shell, which is functionalised with a bone-targeting peptide. In use, the peptide targets the biospecific agent to bone. The bone biospecific agent can be used in diagnostic imaging techniques, such as MRI and CT, and in imaging bone remodelling activities, detecting and treating pathological bone conditions and/or bone repair processes. The invention extends to the diagnosis and/or treatment of bone disease and bone pathologies using the biospecific agents.